Renal cell carcinoma (RCC) is typically found in the older age group between 50 and 70 years of age. However, diagnosis of renal cancer is increasing more rapidly in patients less than 40 years if age compared to older age patients.

Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop.

This article explains how to support a loved one after cancer treatment.

Gretchen Vaughan, Kidney Cancer Association, has been named chief executive officer of the nonprofit.

Kidney cancer had the sharpest annual increase for young Americans: 6.23% between 1995 and 2014.

According to recent research conducted by Spectrum Health, certain factors such as diastolic blood pressure and fasting insulin were found to be associated with renal cell carcinoma.

Sunitinib is administered on a rigid schedule that may not be optimal for all patients. We hypothesised that toxicity-driven dose and schedule changes would optimise drug exposure and outcome for each patient.

This study evaluates whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC).

Personalised treatment plans may extend life expectancy for early-stage kidney cancer patients who have risk factors for worsening kidney disease, according to a new study published in the journal Radiology.

Researchers at the Dana-Farber Cancer Institute are working to develop a vaccine for the treatment of renal cell cancer.